samedan logo

 
 
spacer
home > ict > winter 2017 > out of control
PUBLICATIONS
International Clinical Trials

Out of Control

The first documented outbreak of the Ebola virus disease – more commonly known as Ebola – occurred in 1976 in South Sudan and the Democratic Republic of the Congo. Nearly 40 years later in 2013, the most widespread outbreak of Ebola in history started in the West African country of Guinea and quickly spread to the neighbouring countries of Liberia and Sierra Leone.

While previous outbreaks were brought under control within a matter of weeks, this one became an epidemic that raged on for over two years, resulting in more than 11,000 deaths and significant social disruption. A number of factors contributed to the failure to control this flare-up, including extreme poverty in the affected areas; a dysfunctional healthcare system in affected countries; a population with enormous distrust of government officials after years of armed conflict; several months of delay in government agency response to the outbreak; and the unprecedented spread of Ebola to densely populated cities.

Even with previous Ebola epidemics on record, there were no licensed vaccines, no treatments with proven efficacy in humans and no diagnostics that met the WHO’s target product profile for a rapid, simple Ebola virus disease test at the start of this spread. The lack of effective treatments, combined with the severity of the breakout, triggered an unprecedented global response to tackle the epidemic that provides a compelling case study for accelerated drug development models.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
goBalto’s Chief Executive Officer Sujay Jadhav has over 20 years of experience with leading Silicon Valley software providers with a life sciences focus. Most recently, he was Senior Vice President of Global Corporate Strategy and Development at Model N, and held a variety of roles in Strategy Consulting at Booz Allen Hamilton, Product Strategy at CommerceOne and General Management at Singapore Telecom. Sujay received his Bachelor’s degree from the University of South Australia and an MBA from Harvard University, US.
spacer
Sujay Jadhav
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma and Hansa Biopharma initiate a new Contract Development and Manufacturing project in immunological diseases

Vilnius, Lithuania, and Lund, Sweden - December 20th, 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced a new service agreement to develop the next generation of IgG cleaving enzymes.
More info >>

White Papers

Crossing the Blood Brain Barrier (BBB): Which Route to Take?

Aptar Pharma

Aptar Pharma recently hosted an expert panel/roundtable on the various approaches to treating central nervous system (CNS) diseases. This international scientific forum was held in Paris, France on December 5th, 2014. The roundtable was organized to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood brain barrier (BBB) and successfully treating a host of CNS diseases.
More info >>

 
Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement